Prosecution Insights
Last updated: October 08, 2026

Mercury Bio Inc.

1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Mercury Bio Inc. currently has 1 pending office action in its patent portfolio. This active matter is assigned to 1 distinct examiner, concentrating the current prosecution efforts on a single individual. The data shows 0 distinct art units associated with the current pending actions, which may reflect a specific administrative status. This lack of art unit diversity suggests a highly specialized or unique filing status.

MARIA MARVICH is the busiest examiner for the company, overseeing the busiest examiner pending office action. This single action accounts for the entirety of the portfolio's active workload. With only a single examiner involved, the current prosecution landscape is highly centralized, requiring focused interaction with this official to resolve the outstanding matter. The absence of multiple examiners simplifies the coordination of legal responses for the company.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

0
Life Sciences
0% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
100% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MARVICH, MARIA 1 54.9% +28.1%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18949090 TARGETED EXTRACELLULAR VESICLES FOR DELIVERY OF THERAPEUTICS MARVICH, MARIA —

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18949090 TARGETED EXTRACELLULAR VESICLES FOR DELIVERY OF THERAPEUTICS MARVICH, MARIA — §112DP Non-Final OA — Pending Nov 15, 2024

Managing Mercury Bio Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Mercury Bio Inc. have?

Mercury Bio Inc. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.

Which USPTO examiner handles the most Mercury Bio Inc. applications?

Maria Marvich has the most, with 1 of Mercury Bio Inc.'s pending office actions.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month